Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Udaya Kompella to Humans

This is a "connection" page, showing publications Udaya Kompella has written about Humans.

 
Connection Strength
  
 
 
0.493
  
  1. Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog Retin Eye Res. 2021 05; 82:100901.
    View in: PubMed
    Score: 0.020
  2. Kelley RA, Ghaffari A, Wang Y, Choi S, Taylor JR, Hartman RR, Kompella UB. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons. J Ocul Pharmacol Ther. 2020 06; 36(5):290-297.
    View in: PubMed
    Score: 0.019
  3. Kompella UB, Domb A, Urtti A, Jayagopal A, Wilson CG, Tang-Liu D. ISOPT Clinical Hot Topic Panel Discussion on Ocular Drug Delivery. J Ocul Pharmacol Ther. 2019 10; 35(8):457-465.
    View in: PubMed
    Score: 0.018
  4. Patil MA, Upadhyay AK, Hernandez-Lagunas L, Good R, Carpenter TC, Sucharov CC, Nozik-Grayck E, Kompella UB. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature. Artif Cells Nanomed Biotechnol. 2018; 46(sup3):S1059-S1066.
    View in: PubMed
    Score: 0.017
  5. Hartman RR, Kompella UB. Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. J Ocul Pharmacol Ther. 2018 Jan/Feb; 34(1-2):141-153.
    View in: PubMed
    Score: 0.016
  6. Yavuz B, Kompella UB. Ocular Drug Delivery. Handb Exp Pharmacol. 2017; 242:57-93.
    View in: PubMed
    Score: 0.015
  7. Kulkarni SS, Kompella UB. Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma. J Glaucoma. 2014 Oct-Nov; 23(8 Suppl 1):S77-9.
    View in: PubMed
    Score: 0.013
  8. Rao VR, Upadhyay AK, Kompella UB. pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids. J Control Release. 2013 Nov 28; 172(1):341-350.
    View in: PubMed
    Score: 0.012
  9. Baid R, Upadhyay AK, Shinohara T, Kompella UB. Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein. J Biol Chem. 2013 Jun 14; 288(24):17372-83.
    View in: PubMed
    Score: 0.012
  10. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013 Sep; 36:172-98.
    View in: PubMed
    Score: 0.012
  11. Kompella UB. Nanotechnology and drug delivery. J Ocul Pharmacol Ther. 2013 Mar; 29(2):89.
    View in: PubMed
    Score: 0.012
  12. Kadam RS, Scheinman RI, Kompella UB. Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Mol Pharm. 2012 Nov 05; 9(11):3228-35.
    View in: PubMed
    Score: 0.011
  13. Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res. 2012 May; 98:23-7.
    View in: PubMed
    Score: 0.011
  14. Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion. 2012 Mar; 12(2):190-201.
    View in: PubMed
    Score: 0.011
  15. Baid R, Scheinman RI, Shinohara T, Singh DP, Kompella UB. LEDGF(1-326) decreases P23H and wild type rhodopsin aggregates and P23H rhodopsin mediated cell damage in human retinal pigment epithelial cells. PLoS One. 2011; 6(9):e24616.
    View in: PubMed
    Score: 0.011
  16. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011 07; 129(7):914-20.
    View in: PubMed
    Score: 0.010
  17. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010 Sep; 1(3):435-56.
    View in: PubMed
    Score: 0.010
  18. Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5804-16.
    View in: PubMed
    Score: 0.010
  19. Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv. 2010 May; 7(5):631-45.
    View in: PubMed
    Score: 0.010
  20. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond). 2010 Apr; 5(3):485-505.
    View in: PubMed
    Score: 0.010
  21. Mayo AS, Ambati BK, Kompella UB. Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int J Pharm. 2010 Mar 15; 387(1-2):278-85.
    View in: PubMed
    Score: 0.009
  22. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009 Dec 01; 15(23):7299-308.
    View in: PubMed
    Score: 0.009
  23. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009 Jun; 8(6):1655-65.
    View in: PubMed
    Score: 0.009
  24. Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther. 2009 Apr; 25(2):97-103.
    View in: PubMed
    Score: 0.009
  25. Christie JG, Kompella UB. Ophthalmic light sensitive nanocarrier systems. Drug Discov Today. 2008 Feb; 13(3-4):124-34.
    View in: PubMed
    Score: 0.008
  26. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther. 2008 Feb; 324(2):749-58.
    View in: PubMed
    Score: 0.008
  27. Kompella UB. Drug delivery to the back of the eye. Arch Soc Esp Oftalmol. 2007 Nov; 82(11):667-8; 669-70.
    View in: PubMed
    Score: 0.008
  28. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis. 2007 May 23; 13:746-57.
    View in: PubMed
    Score: 0.008
  29. Raghava S, Kompella UB. AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. Eur J Pharmacol. 2007 Jul 30; 568(1-3):68-74.
    View in: PubMed
    Score: 0.008
  30. Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit. Expert Opin Drug Deliv. 2007 Jan; 4(1):77-85.
    View in: PubMed
    Score: 0.008
  31. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006 Mar; 47(3):1149-60.
    View in: PubMed
    Score: 0.007
  32. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004 Nov; 1(1):99-114.
    View in: PubMed
    Score: 0.007
  33. Koushik K, Bandi N, Sundaram S, Kompella UB. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res. 2004 Jun; 21(6):1034-46.
    View in: PubMed
    Score: 0.006
  34. Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer. Biomed Pharmacother. 2024 Jan; 170:116037.
    View in: PubMed
    Score: 0.006
  35. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol. 2003 Sep; 55(9):1199-206.
    View in: PubMed
    Score: 0.006
  36. Koushik K, Sunkara G, Gwilt P, Kompella UB. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm Res. 2003 May; 20(5):779-87.
    View in: PubMed
    Score: 0.006
  37. Ayalasomayajula SP, Kompella UB. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur J Pharmacol. 2002 Aug 09; 449(3):213-20.
    View in: PubMed
    Score: 0.006
  38. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002 Mar; 19(3):278-85.
    View in: PubMed
    Score: 0.005
  39. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961.
    View in: PubMed
    Score: 0.005
  40. Bandi N, Kompella UB. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol. 2002 Feb 15; 437(1-2):9-17.
    View in: PubMed
    Score: 0.005
  41. Dube T, Kompella UB, Panda JJ. Near infrared triggered chemo-PTT-PDT effect mediated by glioma directed twin functional-chimeric peptide-decorated gold nanoroses. J Photochem Photobiol B. 2022 Mar; 228:112407.
    View in: PubMed
    Score: 0.005
  42. Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, Abdelkader H. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021 06; 11(3):866-893.
    View in: PubMed
    Score: 0.005
  43. Liu Z, Kompella UB, Chauhan A. Gold nanoparticle synthesis in contact lenses for drug-less ocular cystinosis treatment. Eur J Pharm Biopharm. 2021 Aug; 165:271-278.
    View in: PubMed
    Score: 0.005
  44. Aukunuru JV, Sunkara G, Bandi N, Thoreson WB, Kompella UB. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm Res. 2001 May; 18(5):565-72.
    View in: PubMed
    Score: 0.005
  45. Kompella UB, Lee VH. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 2001 Mar 01; 46(1-3):211-45.
    View in: PubMed
    Score: 0.005
  46. Lenin R, Nagy PG, Alli S, Rao VR, Clauss MA, Kompella UB, Gangaraju R. Critical role of endoplasmic reticulum stress in chronic endothelial activation-induced visual deficits in tie2-tumor necrosis factor mice. J Cell Biochem. 2018 11; 119(10):8460-8471.
    View in: PubMed
    Score: 0.004
  47. Good RJ, Hernandez-Lagunas L, Allawzi A, Maltzahn JK, Vohwinkel CU, Upadhyay AK, Kompella UB, Birukov KG, Carpenter TC, Sucharov CC, Nozik-Grayck E. MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability. Am J Physiol Lung Cell Mol Physiol. 2018 10 01; 315(4):L584-L594.
    View in: PubMed
    Score: 0.004
  48. Srinivas SP, Goyal A, Talele DP, Mahadik S, Sudhir RR, Murthy PP, Ranganath S, Kompella UB, Padmanabhan P. Corneal epithelial permeability to fluorescein in humans by a multi-drop method. PLoS One. 2018; 13(6):e0198831.
    View in: PubMed
    Score: 0.004
  49. Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.004
  50. Zhang X, Bohner A, Bhuvanagiri S, Uehara H, Upadhyay AK, Emerson LL, Bondalapati S, Muddana SK, Fang D, Li M, Sandhu Z, Hussain A, Carroll LS, Tiem M, Archer B, Kompella U, Patil R, Ambati BK. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. Mol Ther. 2017 07 05; 25(7):1606-1615.
    View in: PubMed
    Score: 0.004
  51. Muralidharan R, Babu A, Amreddy N, Basalingappa K, Mehta M, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
    View in: PubMed
    Score: 0.004
  52. Wang Z, Cheng R, Lee K, Tyagi P, Ding L, Kompella UB, Chen J, Xu X, Ma JX. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):855-64.
    View in: PubMed
    Score: 0.003
  53. Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014 Apr 28; 55(4):2714-30.
    View in: PubMed
    Score: 0.003
  54. Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, Escher P, Haider NB. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. PLoS One. 2014; 9(1):e87942.
    View in: PubMed
    Score: 0.003
  55. Sreekumar PG, Chothe P, Sharma KK, Baid R, Kompella U, Spee C, Kannan N, Manh C, Ryan SJ, Ganapathy V, Kannan R, Hinton DR. Antiapoptotic properties of a-crystallin-derived peptide chaperones and characterization of their uptake transporters in human RPE cells. Invest Ophthalmol Vis Sci. 2013 Apr 17; 54(4):2787-98.
    View in: PubMed
    Score: 0.003
  56. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26.
    View in: PubMed
    Score: 0.003
  57. Kadam R, Bourne D, Kompella U, Aquilante C. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Biol Pharm Bull. 2013; 36(2):245-51.
    View in: PubMed
    Score: 0.003
  58. Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One. 2012; 7(12):e49635.
    View in: PubMed
    Score: 0.003
  59. Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, Yang H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine. 2012 Jul; 8(5):776-83.
    View in: PubMed
    Score: 0.003
  60. Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol. 2011 Feb 01; 12(2):285-92.
    View in: PubMed
    Score: 0.003
  61. Lee VH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst. 1991; 8(2):91-192.
    View in: PubMed
    Score: 0.003
  62. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Olsen TW, Kompella UB, Holers VM, Hageman GS, Gilger BC, Campochiaro PA, Whitcup SM, Wong WT. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5403-20.
    View in: PubMed
    Score: 0.003
  63. Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009 Aug; 58(8):1902-13.
    View in: PubMed
    Score: 0.002
  64. Kim ES, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res. 2009 May; 26(5):1155-61.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)